Group items tagged

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

One of the most challenging aspects of living a healthier lifestyle is trying to accomplish your goals while simultaneously dealing with a hectic schedule. Life is often full of responsibilities, and things can get so hectic that it's difficult to keep track of anything else outside of one's work. As a result, many people sacrifice their physical and mental health for work-which isn't worth it in the long run. While it might not be easy to manage a hectic schedule, there are ways to ease the burden. Here are some of the most popular best-practice tactics when dealing with a busy schedule. Write things down-even the things you'll do for fun One way to help deal with a hectic schedule is to ensure you write everything down. While some might think that it makes everything feel robotic, the fact that you can write down the things you plan to do for fun means you have something to look forward to. It also has the added benefit of bracing yourself mentally for various tasks. It's not easy to be spontaneous with fun events if you're already tired from work. Fortunately, writing things down and making them a part of your schedule can help your body adjust.

Anglo-Swedish drugmaker AstraZeneca said on Monday (January 9) that it had struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease. AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease. Farxiga, whose sales jumped by almost 50 per cent during the first nine months of 2022 to reach $3.2 billion, belongs to a highly competitive class of drugs that includes rivals such as Boehringer Ingelheim and Eli Lilly's Jardiance. AstraZeneca gets about a third of its revenue from cancer drugs, but its heart, kidney and diabetes medicines are its second most lucrative business by sales, generating roughly $6.9 billion of the drugmaker's total revenue of more than $33 billion in the first three quarters of 2022.

Leading pharmaceutical wholesaler Lexon UK has completed a £60 million refinancing deal with HSBC UK to help meet its growth targets in 2022 and beyond. The asset based lending facility will support Lexon's business strategy, including capital expenditure in areas such as new technology and business development. Founded in 1995, the Redditch-based supplier has distribution centres in Leeds, Durham and Dublin, supporting thousands of independent pharmacies. Nimesh Sodha, director at Lexon, said: "We are delighted to have completed this deal - it will help Lexon grow and continue to support independent pharmacies across the UK, as we have done for many years, in fresh and exciting ways.

The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price. The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel disease and psoriasis, has accounted for about one third of the savings. After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions, which have the same quality, safety and efficacy of a branded one. Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to aggressive blood cancers. Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality patient care. NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

Britain on Monday (January 10) put the biggest private health companies on high alert to deliver crucial treatments such as cancer surgery should Omicron overwhelm National Health Service hospitals in England. The United Kingdom's death toll from the Covid-19 pandemic stands at 150,154, the world's seventh worst official Covid toll after the United States, Brazil, India, Russia, Mexico and Peru. Prime minister Boris Johnson has bet on refraining from lockdowns to deal with the Omicron variant which in recent weeks has swept across the UK, albeit with death rates significantly lower than previous waves. In a sign of just how stretched the NHS could become, health secretary Sajid Javid ordered England's NHS to strike a three-month deal with private health companies to allow patients to get treatments such as cancer surgery outside. "Millions of patients have already got their tests and treatment quicker thanks to our existing deal with independent providers," said David Sloman, NHS England chief operating officer and Covid incident director.

Pharmacy bodies are "bitterly disappointed" that the latest deal on the national contract makes no commitment to "fresh funding", with one organisation calling it "the biggest dis-service ever done" to community pharmacy. The only commitment made in monetary terms was one in which NHS England agreed to write off a sum of £100m in excess margin earned by contractors in previous years. This allowance, which can't be seen as new cash injection, was said to have been made in recognition of the pressures facing the sector. The figure - reached after what the the Pharmaceutical Services Negotiating Committee called "a tense period of negotiations" with the Department of Health and Social Care and NHS England - will cover the final two years of the current five-year Community Pharmacy Contractual Framework. The deal was announced by PSNC chief executive Janet Morrison at an annual LPC Conference in Manchester on Thursday (22 September). Welcoming the attendees, she assured everyone that the committee was well aware of the pressures the sector was facing. "I heard how contractors are feeling and their frustrations over growing pressure and lack of financial support from the government. They confirmed that many now are unable to deliver the full range of services, and others are struggling to maintain core levels of services. And the ongoing impact of capacity and workforce crisis is critical, leading to temporary closures.

The NHS has secured a deal for 'Pembrolizumab' to treat women with triple-negative breast cancer. Up to 1,600 women a year affected by high risk triple-negative breast cancer are set to benefit from the confidential deal struck by the NHS and the Merck Sharp and Dohme's (MSD), manufacturer of Pembrolizumab. Triple-negative breast cancer affects around 8,000 women a year - accounting for 15% of all breast cancer cases. This will be the 25th breast cancer treatment fast-tracked to patients through funding from the Cancer Drugs Fund and the second treatment for triple negative breast cancer to be introduced this year on the NHS. NHS chief executive, Amanda Pritchard, said: "This is a hugely significant moment for women - the NHS has struck a new deal to roll out a potentially life-saving drug for patients suffering with the most aggressive form of breast cancer that has been traditionally very difficult to treat.

Bestway operates approximately 750 pharmacies nationwide in the UK under the Well brand. In April 2023, it completed its acquisition of Lexon, which operates 46 pharmacies in the UK under the Knights Pharmacy brand, and Asurex, a wholesale perfume supplier. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal. Colin Raftery, CMA Senior Director of Mergers, said: "Pharmacies are essential public health services, and it's vital that the loss of competition brought about by a deal like this shouldn't leave people with reduced choice or worse services when they need medical support. The CMA will now carefully consider whether the remedy put forward by Bestway will address its concerns and ensure that customers in the affected areas continue to have access to good quality chemists.

The Competition and Markets Authority (CMA) has announced on Tuesday (20 June) that it may consider undertakings offered by Bestway Panacea Holdings, a parent company of Well Pharmacy, which involves divesting seven pharmacy stores under the merger deal with Lexon UK. The Authority said: "CMA considers that there are reasonable grounds for believing that the undertakings offered by Bestway, or a modified version of them, might be accepted by the CMA under the Enterprise Act 2002." Last week, the Authority had announced that the merger of Bestway, and independent pharmacy owner Lexon UK could "lessen the competition between retail pharmacies" in England. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal.

Hey there, folks! Ever find yourself caught up in the throes of pain, wondering if there's a better way to handle it? You're not alone. In fact, according to recent stats, a whopping 93% of people worldwide grapple with pain annually. And get this: 1 in 3 folks deal with it every single day. Crazy, right? But here's the kicker: despite pain being such a prevalent issue, many folks aren't tackling it head-on. Yep, you heard that right. There's a whole lot of suffering going on, and not enough proactive pain management happening. So, what's the solution? Well, that's where our Pain Management Webinar swoops in to save the day! Picture this: an hour jam-packed with enlightening insights, carefully curated to arm you and your team with the tools needed to understand, manage, and ease pain in your patients' lives. Diving Deep: What's Inside the Webinar Alright, buckle up because we're about to dive into the juicy details of what this webinar has in store for you. 1. The Evolving Role of Pharmacists First up, we're shedding light on the evolving role of pharmacists in the realm of pain management. Yep, you heard that right. It's not just about doling out pills anymore. Pharmacists are becoming key players in the fight against pain, and we'll show you exactly how. 2. Decoding Pain Assessment Ever struggle to figure out just how much pain your patients are in? We feel you. That's why we're dedicating some time to decode the art of pain assessment. By the time you're done with this segment, you'll be a pro at understanding and quantifying your patients' pain levels. 3. #ListenToPain: A Campaign for Better Conversations And last but certainly not least, we're shining a spotlight on Haleon's #ListenToPain campaign. This bad boy is all about fostering better conversations between you and your patients. Trust us, folks, communication is key when it comes to pain management, and this campaign's got all the tools you need to nail those conversations. Tailored Jus

Bipolar disorder can be a very challenging mental illness to deal with. It is characterized by severe mood swings, from manic highs to depressive lows. Many people with bipolar disorder struggle to live normal, productive lives. However, there are various treatments available that can help manage the symptoms of this condition and improve quality of life. In this article, we will discuss the different treatments for bipolar disorder and how to properly deal with the symptoms. MEDICATIONS One of the most common treatments for bipolar disorder is medication. There are a variety of different medications that can be used to treat the symptoms of bipolar disorder. The type of medication that is prescribed will depend on the individual's specific situation. Some common medications that are used to treat bipolar disorder include mood stabilizers, antipsychotics, and antidepressants. However, it is important to note that these are serious medications and should only be taken under the supervision of a qualified mental health professional. So, never attempt to take these medications on your own.

The Royal College of Nursing (RCN) has expressed "extreme disappointment" that the UK government offered new pay to NHS consultants, while nursing pay deal remain disputed. RCN General Secretary and Chief Executive Pat Cullen has written to new Health Secretary Victoria Atkins demanding fresh negotiations regarding this year's pay deal, and requested an urgent meeting to discuss their dispute. Pat warned that more than 100,000 RCN members in England voted for continued strike action in June, as they feel undervalued. "The government has now shown it has the political will to negotiate on pay reform for some of the highest earners in the NHS in contrast to our members who received the lowest pay rise in the public sector," she wrote in the letter. NHS nursing staff in England was awarded a five per cent pay rise 2023/24, but the union argued that it is not enough to keep up with inflation.

The Royal Pharmaceutical Society (RPS) has said that multi-buy deals on paracetamol violate the existing voluntary sales guidelines. The professional body is urging the government to pass legislation that prohibits retailers from making such offers on medicines for pain relief. They have also sent letters to MP Maria Caulfield who is the Minister for Mental Health and Women's Health. The Medicines and Healthcare Products Regulatory Agency (MHRA) is requesting to take action on the legislation at the earliest. The concern raised is that multi-buy offers such as 'buy one get one free' can encourage people to buy and store excess packs, which may lead to accidental or impulsive overdose.

German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said. The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding the company's footprint in the UK, BioNTech said in a statement on Thursday (January 5). Under the agreement, the parties plan to utilise UK's clinical trial network, genomics and health data assets, aiming to enrol the first cancer patient in the second half of 2023, the company said.

The National Pharmacy Association (NPA) has raised concerns over the upcoming increase in the National Living Wage, saying it will make things even worse for local pharmacies already facing nearly a decade of cuts in real terms. Scheduled to go up from £10.42 to £11.44 per hour starting April, the National Living Wage rise is expected to put a lot of financial pressure on many pharmacies. The NPA says "it will cost them over £10,000 in salary bills, and for some, even more, without getting more from the NHS funds. and has asked the government to deal with the ongoing problem of underfunding for community pharmacies. The association has warned that without additional funds, pharmacies could face staff layoffs or reduced services to cover the increased wages, calling for a "comprehensive new funding deal to prevent further closures of vital local services, which have been shutting at the rate of eight a week."

PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.

Social anxiety and its allied depression are very common in every other individual nowadays. It is given the third rank by the connoisseurs who deal with a psychic disorder or say mental health. US Government epidemiological statistics unveil that at any given time the % of people suffering from social anxiety is 7% and in certain or under specific conditions the % of social suffering due to anxiety goes higher to 13% of the population at any given time...

The Healthcare industry, in almost every country, is under pressure to combat the seriousness of coronavirus pandemic. The number one step for managing this catastrophe is by dealing with hundreds and even thousands of diagnostics procedures, and this code will help deal with the billing matters.

The Healthcare industry, in almost every country, is under pressure to combat the seriousness of coronavirus pandemic. The number one step for managing this catastrophe is by dealing with hundreds and even thousands of diagnostics procedures, and this code will help deal with the billing matters.